While growth in Japan rebounded, the bright spot in Asia...

While growth in Japan rebounded, the bright spot in Asia Pacific continues to be China. The combination of a healthy economy and increasing diagnosis and treatment rates make China extremely attractive to multinational pharmaceutical companies. Many of them are expanding their presence in China now because they recognize the significant long-term business opportunities that market presents.